Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Charlotte A. Bradbury"'
Autor:
Akshay Shah, Killian Donovan, Anna McHugh, Manish Pandey, Louise Aaron, Charlotte A. Bradbury, Simon J. Stanworth, Raza Alikhan, Stephen Von Kier, Keith Maher, Nicola Curry, Susan Shapiro, Matthew J. Rowland, Matt Thomas, Richard Mason, Matthew Holland, Tom Holmes, Michael Ware, Stefan Gurney, Stuart R. McKechnie
Publikováno v:
Critical Care, Vol 24, Iss 1, Pp 1-10 (2020)
Abstract Background Optimal prophylactic and therapeutic management of thromboembolic disease in patients with COVID-19 remains a major challenge for clinicians. The aim of this study was to define the incidence of thrombotic and haemorrhagic complic
Externí odkaz:
https://doaj.org/article/dcffec0e330a47f5aaa8e5024b16cb2f
Autor:
Alexander T. Cohen, Gary Benson, Charlotte A. Bradbury, Satarupa Choudhuri, Nathan Hutchinson Jones, Anthony Maraveyas, Balaji Venugopal, Annie M. Young, Chris Chapman, Shauna McIntyre, Danny Burney, Kevin G. Pollock, Angharad R. Morgan, Peter D. Gabb, Raza Alikhan
Publikováno v:
Current Medical Research and Opinion. 39:483-495
Autor:
Sam Schulman, Michelle Sholzberg, Alex C. Spyropoulos, Ryan Zarychanski, Helaine E. Resnick, Charlotte A. Bradbury, Jean Marie Connors, Anna Falanga, Toshiaki Iba, Scott Kaatz, Jerrold H. Levy, Saskia Middeldorp, Tracy Minichiello, Eduardo Ramacciotti, Charles Marc Samama, Jecko Thachil, Lisa Broxmeyer, null International Society on Thrombosis and Haemostasis
Publikováno v:
Journal of thrombosis and haemostasis, 20(10), 2214-2225. Wiley-Blackwell
2022, ' ISTH guidelines for antithrombotic treatment in COVID-19 ', Journal of Thrombosis and Haemostasis, vol. 20, no. 10, pp. 2214-2225 . https://doi.org/10.1111/jth.15808
Journal of Thrombosis and Haemostasis, 20, 2214-2225
Journal of Thrombosis and Haemostasis, 20, 10, pp. 2214-2225
2022, ' ISTH guidelines for antithrombotic treatment in COVID-19 ', Journal of Thrombosis and Haemostasis, vol. 20, no. 10, pp. 2214-2225 . https://doi.org/10.1111/jth.15808
Journal of Thrombosis and Haemostasis, 20, 2214-2225
Journal of Thrombosis and Haemostasis, 20, 10, pp. 2214-2225
Contains fulltext : 282327.pdf (Publisher’s version ) (Closed access) Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with coronavirus disease 2019 (COVID-19) may realize additional benefits from heparins. Op
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63c98fdd43645a7a7eae119a5ed1a26d
https://pure.amc.nl/en/publications/isth-guidelines-for-antithrombotic-treatment-in-covid19(83f1bdb5-2c91-4f60-b3cf-32d76d492231).html
https://pure.amc.nl/en/publications/isth-guidelines-for-antithrombotic-treatment-in-covid19(83f1bdb5-2c91-4f60-b3cf-32d76d492231).html
Autor:
Rosemary Greenwood, Katie Breheny, Ian Thomas, Nichola Cooper, Quentin Hill, Kate Talks, Rachel Rayment, Catherine Bagot, Charlotte A Bradbury, Jenny Ingram, Gillian Evans, Rebecca Kandiyali, Julie Pell
Publikováno v:
Bradbury, C A, Ingram, J, Kandiyali, R, Breheny, K & Greenwood, R 2021, ' Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia ', New England Journal of Medicine, vol. 385, no. 10, pp. 885-895 . https://doi.org/10.1056/NEJMoa2100596
BACKGROUND Immune thrombocytopenia (ITP) is a rare autoimmune thrombocytopenia with associated bleeding risk and fatigue. Recommended first line ITP treatment is with high dose glucocorticoids but side effects, heterogeneous responses and high relaps
Autor:
Madeleine L, Stimpson, Julia S, Wolf, Emily L, Williams, Philippa J P, Lait, Lauren P, Schewitz-Bowers, Rosemary, Greenwood, Julie, Pell, Ian, Thomas, Richard W J, Lee, Charlotte A, Bradbury
Publikováno v:
British journal of haematologyReferences. 196(4)
Autor:
Mary Cushman, Jeffrey S. Berger, Lindsay R. Berry, Jose C. Nicolau, Bryan J. McVerry, Derek C. Angus, Ryan Zarychanski, Brett L. Houston, Jorge Escobedo, Colin McArthur, Roger J. Lewis, Patrick R. Lawler, Michelle N. Gong, Michael E. Farkouh, Elizabeth Lorenzi, Charlotte Ann Bradbury, Anthony C. Gordon, Bridget-Anne Kirwan, Arthur S. Slutsky, David T. Huang, Judith S. Hochman, Anand Kumar, Maria Mori Brooks, Ewan C. Goligher, Steven A. R. Webb, Alexis F. Turgeon, Robert S. Rosenson, Marc Carrier, Scott M. Berry, Zoe McQuilten, Keri S. Kim, Harmony R. Reynolds, Lucy Z. Kornblith, Matthew D. Neal, Susan R. Kahn, Alisa Higgins
BackgroundThrombo-inflammation may contribute to morbidity and mortality in Covid-19. We hypothesized that therapeutic-dose anticoagulation may improve outcomes in non-critically ill patients hospitalized for Covid-19.MethodsIn an open-label adaptive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2eb87171a7317e44aafcf8e8a74bf242
https://doi.org/10.1101/2021.05.13.21256846
https://doi.org/10.1101/2021.05.13.21256846
Autor:
Alexis F. Turgeon, Roger J. Lewis, Tobias Tritschler, Bryan J. McVerry, Lucas C. Godoy, Jeffrey S. Berger, Marc Carrier, Derek C. Angus, Patrick R Lawler, Ryan Zarychanski, Anthony C. Gordon, Scott M. Berry, Keri S. Kim, Maria M. Brooks, John Marshall, Harmony R. Reynolds, Ewan C Goligher, Judith S. Hochman, Lennie P. G. Derde, Bridget-Anne Kirwan, Michelle N. Gong, Charlotte Ann Bradbury, Mary Cushman, Lucy Z. Kornblith, Michael E. Farkouh, Matthew D. Neal, Zoe McQuilten, Anand Kumar, Susan R. Kahn, Brett L. Houston, Steven A R Webb, Colin McArthur
BackgroundThrombosis may contribute to morbidity and mortality in Covid-19. We hypothesized that therapeutic anticoagulation would improve outcomes in critically ill patients with Covid-19.MethodsWe conducted an open-label, adaptive, multiplatform, r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf92249cb690a3cb4c5acba19996454f
https://doi.org/10.1101/2021.03.10.21252749
https://doi.org/10.1101/2021.03.10.21252749
Autor:
Emily L, Williams, Madeleine L, Stimpson, Philippa J P, Lait, Lauren P, Schewitz-Bowers, Lauren V, Jones, Ashwin D, Dhanda, Richard W J, Lee, Charlotte A, Bradbury
Publikováno v:
British journal of haematologyReferences. 192(2)
Immune thrombocytopenia (ITP) is thought to result from an aberrant adaptive autoimmune response, involving autoantibodies, B and T lymphocytes, directed at platelets and megakaryocytes. Previous reports have demonstrated skewed CD4
Autor:
Madeleine L, Stimpson, Philippa J P, Lait, Lauren P, Schewitz-Bowers, Emily L, Williams, Kimberley F, Thirlwall, Richard W J, Lee, Charlotte A, Bradbury
Publikováno v:
Journal of thrombosis and haemostasis : JTHREFERENCES. 18(10)
Corticosteroids remain the first-line treatment for patients with immune thrombocytopenia (ITP). However, 20% to 30% of patients do not respond to treatment at tolerable doses. This variation in corticosteroid efficacy is replicated in other autoimmu
Autor:
Charlotte A Bradbury, Rosemary Greenwood, Julie Pell, Katie Breheny, Rebecca Kandiyali, Jenny Ingram, Ian Thomas, Catherine Bagot, Quentin Hill, HaemSTAR Collaborators, Nichola Cooper
Publikováno v:
Blood. 136:LBA-2
BACKGROUND Immune thrombocytopenia (ITP) is a rare autoimmune condition associated with bleeding risk and fatigue. Current first line ITP treatment is with high dose corticosteroids but frequent side effects, heterogeneous responses and high relapse